State-Based and Demographic Variation in Parent-Reported Medication Rates for Attention-Deficit/Hyperactivity Disorder, 2007–2008

Navigate This Article

Susanna N. Visser, MS; Stephen J. Blumberg, PhD; Melissa L. Danielson, MSPH; Rebecca H. Bitsko, PhD; Michael D. Kogan, PhD

Suggested citation for this article: Visser SN, Blumberg SJ, Danielson ML, Bitsko RH, Kogan MD. State-Based and Demographic Variation in Parent-Reported Medication Rates for Attention-Deficit/Hyperactivity Disorder, 2007–2008. Prev Chronic Dis 2013;10:20073. DOI: http://dx.doi.org/10.5888/pcd9.120073

PEER REVIEWED

Abstract

Medication is the most effective treatment of attention-deficit/hyperactivity disorder (ADHD), a common neurobehavioral disorder of childhood. We used data from the 2007-2008 National Survey of Children’s Health to calculate weighted estimates of parent-reported ADHD and medication treatment among US children aged 4 to 17 years, by state and sex-stratified age. State-based rates of ADHD medication treatment ranged from 33% in Nevada to 79% in Mississippi; rates of medicated ADHD were higher among boys than girls at every age. State-based investigations of ADHD medication treatment factors are needed, and our findings may inform these public health efforts.

Top of Page

Objective

Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder of childhood (1); 4.1 million (7.2%) US school-aged children have a current diagnosis (2). Medication is the single most effective treatment (3,4), and monitoring ADHD treatment patterns is important for improving treatment in this population. We recently published estimates of parent-reported ADHD diagnosis, by state and relevant demographics (2). The objective of this study was to estimate 2007 rates of medication treatment of ADHD, by state and sex-stratified age.

Top of Page

Methods

The National Survey of Children’s Health (NSCH) is a national, random-digit–dialed landline telephone survey of approximately 30 minutes used to characterize the physical, behavioral, and emotional health and health experiences of American children. Conducted twice, the 2007–2008 NSCH had an overall response rate of 46.7%, which incorporates a cooperation rate of 66.0% (5). Nonresponse adjustments were made to the sampling weights to reduce nonresponse bias.
Parents and guardians reported whether they had ever been told by a doctor or health care professional that their child (aged 2-17 y) had attention-deficit disorder or ADHD. Respondents also reported whether the child currently had the disorder. If respondents reported a current diagnosis, they were asked whether the child was currently taking medication for ADHD. We used these data to estimate the percentage of children with current ADHD who were taking medication for ADHD and the rate of medicated ADHD among all US children, calculated by dividing the number of children who were currently taking medication for ADHD by the number of those who had valid responses (ie, those who responded either yes or no) to the current ADHD diagnosis question. We calculated national, state-based, and sex-by-age rates of these 2 indicators.
We restricted the data to 73,122 children aged 4 to 17 years for whom we had valid data on sex and ADHD diagnosis. We incorporated design elements (strata and nonresponse-adjusted weight variables) using SUDAAN version 10.0 (RTI International, Research Triangle Park, North Carolina) to account for the complex survey design and percentages of children taking medication for ADHD treatment by state and sex-stratified age. We compared the prevalence of ADHD medication by sex at each age by using χ² tests and Wald F tests.

Top of Page

Results

Of US children aged 4 to 17 years, 4.1 million (7.2%) had a current ADHD diagnosis in 2007, and approximately 2.7 million were taking ADHD medication. The percentage of children with current ADHD and taking ADHD medication was 4.8% (Table), which represents 66.3% of those with a current ADHD diagnosis.
Among children aged 4 to 17 years, current ADHD was associated with increasing age and male sex (Figure); rates were significantly higher among boys aged 5 to 17 years (χ² test, P < .05). Medication treatment rates by age were significantly different as a function of sex (age-by-sex interaction: F_13,73,121 = 2.08; P = .01); rates of medication treatment increased during early childhood for both sexes, leveled off among older girls, and decreased among teenaged boys. Medication rates were higher among boys than girls at every age.
Bar chart

Figure. Parent-reported current attention-deficit/hyperactivity disorder (ADHD) and ADHD medication treatment among US children, by age and sex, National Survey of Children’s Health, 2007–2008. [A tabular version of this figure is also available.]

The lowest state-based rates of medicated ADHD were documented in 5 Western states (Nevada, California, Alaska, Hawaii, and New Mexico); the highest rates were documented in 5 Southern states (North Carolina, Louisiana, West Virginia, Arkansas, and Delaware). The percentage of children with current ADHD taking ADHD medication was lowest in Nevada, Alaska, and California and highest in Iowa, Missouri, and Mississippi. The national rate of medication treatment among children with current ADHD was 66.3% (95% confidence interval, 63.0-69.4); state-based rates ranged from 33% in Nevada to 79% in Mississippi.